News | Myriad Genetics

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

May 07, 2026 | Financial

Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business

May 05, 2026 | Financial

Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan

Apr 30, 2026 | Products

Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026

Apr 28, 2026 | Financial | Corporate

Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026

Apr 16, 2026 | Products

Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan

Apr 14, 2026 | Products

Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting

Apr 09, 2026 | Products

Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer

Mar 17, 2026 | Products

Myriad Commercially Launches Precise MRD with Select Community Oncologists

Mar 02, 2026 | Products

Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests

Feb 24, 2026 | Products

Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution

Feb 23, 2026 | Corporate | Financial

FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test

Feb 19, 2026 | Products

Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

Feb 16, 2026 | Corporate | Financial

Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data

Jan 27, 2026 | Products

NASDAQ:

MYGN

$4.21

0%

DAY HIGH

YEAR HIGH

DAY LOW

YEAR LOW

05/11/2026

NASDAQ:

MYGN

$4.21

0%

News Releases

Select year

Categories

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business

Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan

Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026

Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026

Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan

Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting

Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer

Myriad Commercially Launches Precise MRD with Select Community Oncologists

Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests

Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution

FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test

Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance

Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference